Athenex announces agreement with immunitybio regarding dunkirk manufacturing facility

Buffalo, n.y., jan. 12, 2022 (globe newswire) -- athenex, inc., (nasdaq: atnx), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for immunitybio, inc. (nasdaq: ibrx) to assume its leasehold interest in a manufacturing facility in dunkirk, new york, and certain related assets for approximately $38 million, subject to adjustment at closing. proceeds from the sale will be used to service the company's debt obligations and for other general corporate purposes. the transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022.
ATNX Ratings Summary
ATNX Quant Ranking